Biosimilar Newsletter Archive

1. 05.25.23 -- The Global Market For Biosimilars Through 2032 5/25/2023
   05/25/23 Biosimilar Development Newsletter
2. 05.18.23 -- Final FDA Guidance Defines Suspect & Illegitimate Drug Product 5/18/2023
   05/18/23 Biosimilar Development Newsletter
3. 05.15.23 -- Futureproof The Design Of Your Biomanufacturing Capacity 5/15/2023

   05/15/23 Biosimilar Development Newsletter

4. 05.11.23 -- How Can Life Sciences Navigate M&A In 2023 5/11/2023
   05/11/23 Biosimilar Development Newsletter
5. 05.09.23 -- Controlling Raw Material Variability 5/9/2023
   05/09/23 Biosimilar Development Newsletter
6. 05.04.23 -- Best Practices For Cell Culture Media Fingerprinting 5/4/2023
   05/04/23 Biosimilar Development Newsletter
7. 05.03.23 -- Containment Considerations As You Develop Your Drug Product 5/3/2023
   05/03/23 Biosimilar Development Newsletter
8. 04.28.23 -- Evolving Design Space Requirements For Biologic Combination Products 4/28/2023

   04/28/23 Biosimilar Development Newsletter

9. 04.27.23 -- Draft FDA Labeling Guidance Proposes More Clarity For Providers 4/27/2023
   04/27/23 Biosimilar Development Newsletter
10. 04.25.23 -- Driving Down The Cost Of Goods For Viral Gene Therapies 4/25/2023

    04/25/23 Biosimilar Development Newsletter